Kent and Medway Medical School
10 imported, source-linked research records. Published in the last five years.
10 matching research records
Topic: Canagliflozin and SGLT2. Only records linked to Kent and Medway Medical School are included. Historical ingestion is still running; these are imported records, not a count of all research worldwide.
Showing 1–10 of 10 matching records. Counts update as records arrive.
Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
May 6, 2023 · 37 citations · Open access
Open original record →Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong
March 31, 2023 · 24 citations · Open access
Open original record →Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset hip fracture risks in patients with type-2 diabetes: A propensity score-matched study with competing risk analysis
February 19, 2023 · 0 citations · Open access
Open original record →Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: A propensity score-matched study with competing risk analysis
October 29, 2022 · 20 citations · Open access
Open original record →Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes patients: a propensity score-matched study
October 1, 2022 · 2 citations · Open access
Open original record →Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
September 6, 2022 · 38 citations
Open original record →Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver disease and hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study
August 17, 2022 · 5 citations · Open access
Open original record →Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
February 10, 2022 · 48 citations · Open access
Open original record →Incident Heart Failure and Myocardial Infarction in Sodium-Glucose Cotransporter-2 vs. Dipeptidyl Peptidase-4 Inhibitor Users
February 7, 2022 · 28 citations · Open access
Open original record →Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
October 21, 2021 · 112 citations · Open access
Open original record →